Dr Piotr Iwanowski appointed as Chief Medical Officer and Board Member of Molecure

Warsaw, 1 August 2024 r. – Molecure S.A. (‘Molecure’, WSE ticker: MOC), a biotechnology company that discovers and develops drugs to the clinical stage and leverages its globally unique expertise in medicinal chemistry and biology to explore and develop first-in-class small-molecule drugs that directly modulate protein activity and mRNA function to treat a wide range of incurable diseases, announces the appointment of Piotr Iwanowski, M.D., Ph.D., as Chief Medical Officer (CMO) and Board Member of Molecure S.A., effective as of 30 September 2024.

 

„We are delighted that Piotr is joining the Molecure team. He is a high-level professional with many years of experience in the management, design, medical monitoring, oversight, and reporting of international clinical trials, with multiple interactions with regulators, including EMA and FDA. Piotr has been involved in the planning and execution of dozens of international clinical trials on all continents, both early and late stage. Several drugs from clinical trials in which Piotr had a significant impact at the operational level have already reached the market’’ says Marcin Szumowski, CEO of Molecure. ,,Piotr has already been co-operating with Molecure as a consultant in our clinical programs, scientific advise and other regulatory procedures. His expert knowledge and familiarity with Molecure’s research programs are key assets and will allow him to quickly establish himself in the effective management of Molecure’s clinical team, crucial in accelerating their progress and building Molecure’s value” – adds Marcin Szumowski.

 

„I am honored to have the opportunity to join such an innovative Polish biotechnology company. Having worked for more than 20 years in international teams involved in the clinical development of drugs and medical devices, I am delighted that I can now apply my experience in a domestic biotech company. I assume that my knowledge of clinical trials, both early and late phases, will be crucial to the development of the company’s promising portfolio. I am enthusiastic about the upcoming collaboration with the talented Molecure team. Together, we will accelerate innovations under development to deliver new, effective and safe therapies for patients in Poland and around the world” – says Dr Piotr Iwanowski.

 

Piotr Iwanowski is a doctor of medicine and an expert with extensive international experience in the clinical development of medicinal products and medical devices, which he acquired in various roles including senior medical positions. His responsibilities have included management of the clinical teams, interactions with principal investigators at clinical sites involved in ongoing clinical trials, study design, shaping the clinical development strategy, medical and regulatory supervision of clinical trial progress, scientific procedures with regulators, scientific publications, as well as support of business development processes from the clinical end.

Previously, Piotr served as associate vice president of clinical research in Europe at Wockhardt Bio and associate director of clinical operations in CEE and Turkey at Bristol-Myers Squibb. He also has several years of experience as a manager, monitor and auditor of clinical trials at Servier Poland. Since 2017, he has been a consultant physician at the Centre for Rare Diseases at the Children’s Memorial Health Intitute in Warsaw.

Piotr Iwanowski graduated in medicine and obtained his thesis in medical sciences at the Medical University of Białystok and specialized in clinical genetics. He completed postgraduate studies in medical law, bioethics and sociology of medicine at the University of Warsaw. He is fluent in Polish, English, French, German and Russian.

He has authored numerous scientific publications in the field of clinical drug development, including a co-authored publication with the Molecure team on arginase inhibitors.

He plays an active role in various scientific and educational organizations, including as a lecturer and faculty member for public grant application evaluation. He has also held positions in the Polish Association for Good Clinical Practice, including vice-president and board member.

 

***

About Molecure S.A.

Molecure S.A. is a biotechnology company that discovers and develops drugs to the clinical stage, leveraging its own unique expertise in medicinal chemistry and biology to search for and develop first-in-class small-molecule drugs that, through direct modulation of previously unexplored protein and RNA targets, may provide therapies for many incurable diseases.

Molecure has generated a diverse portfolio of seven distinct programs with the support of leading academic research institutions around the world, including Yale University, Rutgers University, the Flemish Institute for Biotechnology (VIB) in Ghent, the University of Michigan and the International Institute of Molecular and Cell Biology in Warsaw (MIBMiK).

The most advanced drug candidate developed by Molecure is OATD-01, a first-in-class CHIT1 inhibitor for the treatment of interstitial lung diseases such as sarcoidosis and idiopathic pulmonary fibrosis and MASH, which is in Phase II clinical trials.

The second drug candidate is OATD-02, an oral, selective, first-in-class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer, whose Phase I clinical trial has begun with first patient administration in Q1 2023.

Molecure’s headquarters and laboratories are located in Warsaw and Lodz. The company is listed on the Warsaw Stock Exchange (ticker: MOC).

Detailed information can be found at: https://molecure.com/pl/

LinkedIn: Molecure | Twitter: @molecure_sa | YouTube: Molecure SA